ClinicalTrials.gg
CompletedNCT07933250Updated Nov 12, 2026

Intravitreal Bevacizumab Versus Posterior Sub-Tenon Triamcinolone Acetonide for Treating Diabetic Macular Edema

An interventional study of Bevacizumab Intravitreal Injection and Triamcinolone Acetonide Injection in Diabetic Macular Edema, sponsored by Muhammad Aamir Latif. Completed at 1 site in Pakistan. Open to participants aged 25 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Muhammad Aamir Latif · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Oct 2025, registered Nov 2026).
Updated Nov 12, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
46
Allocation
Non-randomized
Ages
25 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 26 studies testing Triamcinolone Acetonide in Macular Edema — 1 open to participants now, 1 under way, none of them phase 3. Triamcinolone Acetonide · Macular Edema.

Enrollment
15th of 25
46 · median 75
Started
2025
the only one that year
No phase
4 of 26
none open now
Registered
26th of 26
by date

Among the 26 studies testing Triamcinolone Acetonide in Macular Edema, this one is the 15th largest by enrollment of the 25 interventional ones that give a count, is the only one that started in 2025, is one of 4 with no phase, and was the 26th registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 66 are open to participants now.

Browse Macular Edema studies →

Open to participants now

1 of the 26 studies testing Triamcinolone Acetonide in Macular Edema is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Triamcinolone Acetonide

Triamcinolone Acetonide: first FDA approval 1958 (TRIAMCINOLONE ACETONIDE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 44 Macular Edema studies recruiting now, 31 (70%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 25 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing Triamcinolone Acetonide in Macular Edema, or all of them as a file.
02

Study summary

Local data comparing the effects of intravitreal bevacizumab and posterior sub-Tenon triamcinolone acetonide on central macular thickness (CMT) in patients with diabetic macular edema (DME) are scarce. Therefore, the present study was undertaken to evaluate and compare the short-term anatomical outcomes of these two treatments in terms of CMT reduction.

Read the detailed description

Although both intravitreal bevacizumab and posterior sub-Tenon triamcinolone acetonide can improve the anatomical outcomes of DME, treatment response may vary according to the route of corticosteroid administration, baseline disease characteristics, and duration of follow-up. Evidence directly comparing these two treatment approaches remains limited, particularly in local clinical settings. Such a comparison may help clarify their relative short-term anatomical effectiveness and provide locally relevant evidence to guide treatment selection in patients with DME.

03

Conditions studied

  • Diabetic Macular Edema

Browse trials for

04

Who can participate

Ages eligible
25 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients of either gender
  • Aged 25-75 years
  • With DME for more than three months
  • CMT >300 μm.

Exclusion criteria

Exclusion Criteria:

  • Patients with a previous history of intravitreal bevacizumab
  • Previous intraocular surgery
  • Ocular trauma
  • Previous focal/grid laser treatment
  • Media opacities (dense cataract or corneal opacity)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Bevacizumab-Group

    Patients received an intravitreal injection of bevacizumab 1.25 mg/0.05 mL through the pars plana 3.5-4 mm posterior to the limbus under local anesthesia.

    Drug: Bevacizumab Intravitreal Injection

  • Experimental
    Triamcinolone acetonide-Group

    Patients received a posterior sub-Tenon injection of triamcinolone acetonide 1.25 mg under aseptic conditions. The triamcinolone was drawn into a 1-mL syringe and administered using a 26-gauge, 5/8-inch sharp-tipped needle, which was advanced to facilitate deposition within the posterior sub-Tenon space.

    Drug: Triamcinolone Acetonide Injection

Interventions

  • DrugBevacizumab Intravitreal Injection

    Patients received an intravitreal injection of bevacizumab 1.25 mg/0.05 mL through the pars plana 3.5-4 mm posterior to the limbus under local anesthesia.

  • Patients received a posterior sub-Tenon injection of triamcinolone acetonide 1.25 mg under aseptic conditions. The triamcinolone was drawn into a 1-mL syringe and administered using a 26-gauge, 5/8-inch sharp-tipped needle, which was advanced to facilitate deposition within the posterior sub-Tenon space.

06

What researchers measure

Primary outcomes

  1. Central Macular Thickness

    Change in CMT, measured in micrometers (μm), was calculated as baseline CMT minus CMT measured one month after treatment. A positive value indicated a reduction in CMT, whereas a negative value indicated an increase in CMT.

    Time frame: 30 days

07

Study locations

1 site
  • Bahawal Victoria Hospital/Quaid-e-Azam Medical College
    Bahawalpur, Punjab Province 63100, Pakistan
08

References and documents

Individual participant data

Plan to share: No — Data can be shared on a reasonable request.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2025 to primary completion in Jun 2026, 8 months.

Of 47 non-industry interventional studies with no phase under Macular Edema, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 42. This study's 8 months is below that.

Counting every sponsor, half of 51 studies reached it within 18 months; a quarter within 8 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2026
First posted
Nov 12, 2026
StartActual
Oct 1, 2025
Primary completionActual
Jun 30, 2026
CompletionActual
Jun 30, 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07933250
Lead sponsor
Muhammad Aamir Latif
Responsible party
Muhammad Aamir Latif (Research Consultant, RESnTEC, Institute of Research) — Sponsor-investigator
First posted
Nov 12, 2026
Start date
Oct 1, 2025
Primary completion
Jun 30, 2026
Completion
Jun 30, 2026
Last update
Nov 12, 2026

Study contacts

Zulfiqar Ali, FCPS
principal investigator · Bahawal Victoria Hospital/Quaid-e-Azam Medical College Bahawalpur
Nadia Nazir, FCPS
principal investigator · Bahawal Victoria Hospital/Quaid-e-Azam Medical College Bahawalpur

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Triamcinolone Acetonide

Start the discussion